Product Description
Abicipar Pegol is an anti-VEGF molecule based on the designed ankyrin repeat proteins (DARPin) therapeutics (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182559/)
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Macular Degeneration|Neovascular age-related macular degeneration
Phase 2: Macular Degeneration|Macular Edema
Phase 1: Macular Degeneration|Macular Edema|Wet Macular Degeneration
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03335852 |
PINE | P1 |
Completed |
Macular Degeneration |
2018-10-08 |
21% |
2019-03-21 |
|
NCT02859766 |
NCT02859766 | P1 |
Completed |
Macular Degeneration |
2017-10-20 |
2019-03-20 |
Treatments |
|
NCT01042678 |
MP0112-CP02 | P1 |
Terminated |
Macular Edema |
2010-12-01 |
2019-03-19 |
Treatments |
|
NCT01086761 |
MP0112-CP01 | P1 |
Terminated |
Wet Macular Degeneration |
2010-11-01 |
2019-03-19 |
Treatments |
|
NCT03539549 |
NCT03539549 | P2 |
Completed |
Macular Degeneration |
2019-02-27 |
59% |
2020-08-05 |
|
NCT02181504 |
BAMBOO | P2 |
Completed |
Macular Degeneration |
2015-12-01 |
2019-03-20 |
Treatments |
|
NCT02186119 |
PALM | P2 |
Completed |
Macular Edema |
2015-06-01 |
2019-03-20 |
Treatments |
|
NCT02181517 |
CYPRESS | P2 |
Completed |
Macular Degeneration |
2015-03-01 |
2019-03-20 |
Treatments |
|
2011-002526-43 |
REACH Study | P2 |
Completed |
Macular Degeneration |
2014-04-09 |
2022-03-13 |
Treatments |
|
NCT01397409 |
REACH Study | P2 |
Completed |
Macular Degeneration |
2014-03-31 |
2019-04-17 |
Primary Completion Date|Study Completion Date|Treatments |
|
2014-004579-22 |
CEDAR | P3 |
Completed |
Neovascular age-related macular degeneration |
2019-04-16 |
40% |
2025-06-27 |
Treatments |
2014-004580-20 |
SEQUOIA | P3 |
Completed |
Neovascular age-related macular degeneration |
2019-04-03 |
40% |
2022-03-13 |
Treatments |
NCT02462928 |
CEDAR | P3 |
Completed |
Macular Degeneration |
2018-04-18 |
40% |
2020-07-29 |
Primary Endpoints|Treatments |
NCT02462486 |
SEQUOIA Study | P3 |
Completed |
Macular Degeneration |
2018-04-12 |
40% |
2020-07-31 |
Patient Enrollment|Primary Endpoints|Treatments |